Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response

Transfusion

Volumn 54, Issue 3, 2014, Pages 672-680

  Jackman, Rachael P ^a   Deng, Xutao ^b   Bolgiano, Douglas ^b   Utter, Garth H ^b   Schechterly, Cathy ^b   Lebedeva, Mila ^b   Operskalski, Eva ^b   Luban, Naomi L ^b   Alter, Harvey ^b   Busch, Michael P ^b   Slichter, Sherrill J ^b   Norris, Philip J ^b  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOIMMUNIZATION; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BLOOD TRANSFUSION REACTION; CONTROLLED STUDY; HEPATITIS C; HUMAN; LEUKAPHERESIS; LYMPHOCYTOTOXICITY; MAJOR CLINICAL STUDY; MICROCHIMERISM; TRANSFUSION TRANSMITTED INFECTIOUS DISEASE; ULTRAVIOLET RADIATION; VIRUS TRANSMISSION;

ANTIBODY FORMATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; MALE; ULTRAVIOLET RAYS;

EID: 84896037606     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12317     Document Type: Article

References (48)

1. Cox JV, Steane E, Cunningham G, Frenkel EP,. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med 1988; 148: 2485-2489.
2. Michail-Merianou V, Pamphili-Panousopoulou L, Piperi-Lowes L, Pelegrinis E, Karaklis A,. Alloimmunization to red cell antigens in thalassemia: comparative study of usual versus better-match transfusion programmes. Vox Sang 1987; 52: 95-98.
3. Orlina AR, Unger PJ, Koshy M,. Post-transfusion alloimmunization in patients with sickle cell disease. Am J Hematol 1978; 5: 101-106.
4. Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, Wang W, Levy PS,. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990; 76: 1431-1437.
5. Miller ST, Kim HY, Weiner DL, Wager CG, Gallagher D, Styles LA, Dampier CD, Roseff SD,; Investigators of the Sickle Cell Disease Clinical Research Network (SCDCRN). Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion 2012; 53: 704-709.
6. O'Suoji C, Liem RI, Mack AK, Kingsberry P, Ramsey G, Thompson AA,. Alloimmunization in sickle cell anemia in the era of extended red cell typing. Pediatr Blood Cancer 2013 Mar 18. [Epub ahead of print].
7. Azarkeivan A, Ansari S, Ahmadi MH, Hajibeigy B, Maghsudlu M, Nasizadeh S, Shaigan M, Toolabi A, Salahmand M,. Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. Pediatr Hematol Oncol 2011; 28: 479-485.
8. Kita T, Nei J, Matsu T, Yoshiba H, Matsuda T, Yahagi H, Uchida S, Nakao S,. GVHD after transfusion of stored RBC concentrates in a solution of mannitol, adenine, phosphate, citrate, glucose, and NaCl following trauma. Transfusion 2000; 40: 297-301.
9. O'Connor NT, Mackintosh P,. Transfusion associated graft versus host disease in an immunocompetent patient. J Clin Pathol 1992; 45: 621-622.
10. Triulzi D, Duquesnoy R, Nichols L, Clark K, Jukic D, Zeevi A, Meisner D,. Fatal transfusion-associated graft-versus-host disease in an immunocompetent recipient of a volunteer unit of red cells. Transfusion 2006; 46: 885-888.
11. Gorman TE, Julius CJ, Barth RF, Ng A, Kennedy MS, Prior TW, Allen J, Lasky LC,. Transfusion-associated graft-vs-host disease. A fatal case caused by blood from an unrelated HLA homozygous donor. Am J Clin Pathol 2000; 113: 732-737.
12. Howard JE, Perkins HA,. The natural history of alloimmunization to platelets. Transfusion 1978; 18: 496-503.
13. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R,. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105: 4106-4114.
14. Jackman RP, Deng X, Bolgiano D, Lebedeva M, Heitman JW, Busch MP, Slichter SJ, Norris PJ,. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants. Blood 2013; 121: 3261-3266.
15. Andreu G, Dewailly J, Leberre C, Quarre MC, Bidet ML, Tardivel R, Devers L, Lam Y, Soreau E, Boccaccio C, Piard N, Bidet JM, Genetet B, Fauchet R,. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988; 72: 964-969.
16. Dutcher JP, Schiffer CA, Aisner J, Wiernik PH,. Alloimmunization following platelet transfusion: the absence of a dose-response relationship. Blood 1981; 57: 395-398.
17. Fisher M, Chapman JR, Ting A, Morris PJ,. Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions. Vox Sang 1985; 49: 331-335.
18. Murphy MF, Metcalfe P, Thomas H, Eve J, Ord J, Lister TA, Waters AH,. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 1986; 62: 529-534.
19. Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP,. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983; 62: 815-820.
20. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JW,. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 1991; 77: 201-205.
21. Karpinski M, Pochinco D, Dembinski I, Laidlaw W, Zacharias J, Nickerson P,. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 2004; 15: 818-824.
22. Fauchet R, Genetet B, Gueguen M, Leguerrier A, Rioux C, Logeais Y,. Transfusion therapy and HLA antibody response in patients undergoing open heart surgery. Transfusion 1982; 22: 320-322.
23. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861-1869.
24. Payne R, Rolfs MR,. Further observations on leukoagglutinin transfusion reactions in women: with special reference to leukoagglutinin transfusion reactions in women. Am J Med 1960; 29: 449-458.
25. Holohan TV, Terasaki PI, Deisseroth AB,. Suppression of transfusion-related alloimmunization in intensively treated cancer patients. Blood 1981; 58: 122-128.
26. Oksanen K, Kekomaki R, Ruutu T, Koskimies S, Myllyla G,. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components-a randomized trial. Transfusion 1991; 31: 588-594.
27. Slichter SJ, Bolgiano D, Kao KJ, Kickler TS, McFarland J, McCullough J, Woodson R,. Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products. Transfus Med Rev 2011; 25: 102-110.
28. Terasaki PI, McClelland JD,. Microdroplet assay of human serum cytotoxins. Nature 1964; 204: 998-1000.
29. Phelan DL, Rodey GE, Anderson CB,. The development and specificity of antiidiotypic antibodies in renal transplant recipients receiving single-donor blood transfusions. Transplantation 1989; 48: 57-60.
30. Carrick DM, Johnson B, Kleinman SH, Vorhaben R, Chance SC, Lee JH, Roback JD, Pandey S, Sun Y, Busch MP, Norris PJ,. Agreement among HLA antibody detection assays is higher in ever-pregnant donors and improved using a consensus cutoff. Transfusion 2011; 51: 1105-1116.
31. Fadeyi E, Adams S, Peterson B, Hackett J, Byrne P, Klein HG, Marincola FM, Leitman SF, Stroncek DF,. Analysis of a high-throughput HLA antibody screening assay for use with platelet donors. Transfusion 2008; 48: 1174-1179.
32. Lopes LB, Fabron A Jr, Chiba AK, Ruiz MO, Bordin JO,. Impact of using different laboratory assays to detect human leukocyte antigen antibodies in female blood donors. Transfusion 2010; 50: 902-908.
33. Uboldi de Capei M, Pratico L, Curtoni ES,. Comparison of different techniques for detection of anti-HLA antibodies in sera from patients awaiting kidney transplantation. Eur J Immunogenet 2002; 29: 379-382.
34. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR,. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988; 71: 1402-1407.
35. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, van Dijk BA, van Putten WL, Claas FH, Novotny VM, Brand A,. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995; 85: 824-828.
36. Asano H, Lee CY, Fox-Talbot K, Koh CM, Erdinc MM, Marschner S, Keil S, Goodrich RP, Baldwin WM 3rd,. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007; 84: 1174-1182.
37. Kao KJ,. Effects of leukocyte depletion and UVB irradiation on alloantigenicity of major histocompatibility complex antigens in platelet concentrates: a comparative study. Blood 1992; 80: 2931-2937.
38. Jackman RP, Muench MO, Heitman JW, Inglis HC, Law JP, Marschner S, Goodrich RP, Norris PJ,. Immune modulation and lack of alloimmunization following transfusion with pathogen-reduced platelets in mice. Transfusion 2013. doi: 10.1111/trf.12133.
39. Jackman RP, Heitman JW, Marschner S, Goodrich RP, Norris PJ,. Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment. Transfusion 2009; 49: 2686-2699.
40. Jackman RP, Utter GH, Muench MO, Heitman JW, Munz MM, Jackman RW, Biswas HH, Rivers RM, Tobler LH, Busch MP, Norris PJ,. Distinct roles of trauma and transfusion in induction of immune modulation after injury. Transfusion 2012; 52: 2533-2550.
41. Aach RD, Szmuness W, Mosley JW, Hollinger FB, Kahn RA, Stevens CE, Edwards VM, Werch J,. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med 1981; 304: 989-994.
42. Stevens CE, Aach RD, Hollinger FB, Mosley JW, Szmuness W, Kahn R, Werch J, Edwards V,. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. Ann Intern Med 1984; 101: 733-738.
43. Operskalski EA, Mosley JW, Tobler LH, Fiebig EW, Nowicki MJ, Mimms LT, Gallarda J, Phelps BH, Busch MP,. HCV viral load in anti-HCV-reactive donors and infectivity for their recipients. Transfusion 2003; 43: 1433-1441.
44. Mosley JW, Operskalski EA, Tobler LH, Buskell ZJ, Andrews WW, Phelps B, Dockter J, Giachetti C, Seeff LB, Busch MP,. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat 2008; 15: 120-128.
45. Sanchez R, Lee TH, Wen L, Montalvo L, Schechterly C, Colvin C, Alter HJ, Luban NL, Busch MP,. Absence of transfusion-associated microchimerism in pediatric and adult recipients of leukoreduced and gamma-irradiated blood components. Transfusion 2012; 52: 936-945.
46. Triulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR, Glynn SA, Hillyer CD, Carey P, Gottschall JL, Murphy EL, Rios JA, Ness PM, Wright DJ, Carrick D, Schreiber GB,. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009; 49: 1825-1835.
47. Gallucci S, Lolkema M, Matzinger P,. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5: 1249-1255.
48. Norris PJ, Lee JH, Carrick DM, Gottschall JL, Lebedeva M, de Castro BR, Kleinman SH, Busch MP,. Long-term in vitro reactivity for human leukocyte antigen antibodies and comparison of detection using serum versus plasma. Transfusion 2009; 49: 243-251.